Information Provided By:
Fly News Breaks for September 27, 2016
CBM
Sep 27, 2016 | 09:22 EDT
Stephens analyst Drew Jones lowered his price target for Cambrex to $56 from $63 given the recent pullback in the stock. The analyst believes the recently announced acquisition of PharmaCore broadens the opportunity for Cambrex as it presents the chance to secure relationships much earlier in the regulatory process. Jones continues to like Cambrex's long-term outlook and reiterates an Overweight rating on its shares.
News For CBM From the Last 2 Days
There are no results for your query CBM
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.